Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer

Affiliations

¹ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Urology, Brigham & Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
³ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
⁴ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
⁵ Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁶ Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA.
⁷ Department of Urology, Brigham & Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
⁸ Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁹ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Radiation Oncology, Brigham & Women's Hospital, Boston, MA, USA. Electronic address: kent_mouw@dfci.harvard.edu.

Yuzhen Zhou et al. Eur Urol. 2024 Jul.

. 2024 Jul;86(1):69-71.

doi: 10.1016/j.eururo.2024.03.013. Epub 2024 Mar 23.

¹ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Urology, Brigham & Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
³ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
⁴ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
⁵ Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁶ Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA.
⁷ Department of Urology, Brigham & Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
⁸ Harvard Medical School, Boston, MA, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁹ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Radiation Oncology, Brigham & Women's Hospital, Boston, MA, USA. Electronic address: kent_mouw@dfci.harvard.edu.

No abstract available

Publication types